Pathologists at academic medical centers are using intentional change-management strategies to overcome some intangible barriers digital uptake.

The firm said the low end of its full-year revenue guide remains achievable, despite prelim Q1 revenues dropping approximately 11 percent year over year.

Roche's Foundation Medicine will strengthen its testing portfolio by adding Saga's Pathlight tumor-informed molecular residual disease platform.

Siemens said the has been " substantial progress in the preparation of the unprecedented transaction structure … [and] The separation process is advanced." ...

The expanded panel includes 93 new microorganism-drug combinations, bringing the total panel size to 215, and in conformity with all the most current FDA breakpoints.

Grifols announced on Wednesday that its assay for screening blood donors for malaria risk has been approved by the US Food and Drug Administration. The firm's automated Procleix Plasmodium Assay, used ...

With the mark, the system, a fully automated blood culture platform meant for diagnosing bloodstream infections, can be sold throughout the EU.

The firm intends to use the credit facility for liquidity support for its US dollar-denominated commercial paper program and for general corporate purposes.

The company's first Resolve blood-based multi-cancer detection tests are expected to be commercially available in the second half of 2026.

The test, which leverages technology that mimics a dog's ability to sense disease in humans, analyzes cancer-associated volatile organic compounds found in urine samples.

The Utrecht, Netherlands-based company recently closed a $70 million funding round and published trial results showing its technology's equivalence to manual blood collection.